Evidence map›Paper›PMID 31242645›Full record

ArticleViruses2019

A DNA Prime Immuno-Potentiates a Modified Live Vaccine against the Porcine Reproductive and Respiratory Syndrome Virus but Does Not Improve Heterologous Protection.

Cindy Bernelin-Cottet, Céline Urien, Maxence Fretaud, Christelle Langevin, Ivan Trus, Luc Jouneau, Fany Blanc, Jean-Jacques Leplat, Céline Barc, Olivier Boulesteix and 8 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Non-viral COVID-19 vaccine delivery systems.Advanced drug delivery reviews · 2021
    Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 3 countries.

Cindy Bernelin-CottetVIM, INRA, Université Paris-Saclay, Domaine de Vilvert, 78350 Jouy-en-Josas, France. bernelin.cottet.cindy@hotmail.fr.
Céline UrienVIM, INRA, Université Paris-Saclay, Domaine de Vilvert, 78350 Jouy-en-Josas, France. celine.urien@inra.fr.
Maxence FretaudVIM, INRA, Université Paris-Saclay, Domaine de Vilvert, 78350 Jouy-en-Josas, France. maxence.fretaud@inra.fr.
Christelle LangevinVIM, INRA, Université Paris-Saclay, Domaine de Vilvert, 78350 Jouy-en-Josas, France. christelle.langevin@inra.fr.ORCID 0000-0002-6013-4460
Ivan TrusLaboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, B-9820 Merelbeke, Belgium. ivan.trus@gmail.com.ORCID 0000-0003-2849-5140
Luc JouneauVIM, INRA, Université Paris-Saclay, Domaine de Vilvert, 78350 Jouy-en-Josas, France. luc.jouneau@inra.fr.ORCID 0000-0002-5094-7302
Fany BlancGABI, INRA-AgroParisTech, Université Paris-Saclay, Domaine de Vilvert, 78350 Jouy-en-Josas, France. Fany.blanc@inra.fr.ORCID 0000-0003-2366-9826
Jean-Jacques LeplatGABI, INRA-AgroParisTech, Université Paris-Saclay, Domaine de Vilvert, 78350 Jouy-en-Josas, France. jeanjacques.leplat@inra.fr.
Céline BarcPlate-Forme d'Infectiologie Expérimentale-PFIE-UE1277, Centre Val de Loire, INRA, 37380 Nouzilly, France. celine.barc@inra.fr.
Olivier BoulesteixPlate-Forme d'Infectiologie Expérimentale-PFIE-UE1277, Centre Val de Loire, INRA, 37380 Nouzilly, France. olivier.boulesteix@inra.fr.
Mickaël RiouPlate-Forme d'Infectiologie Expérimentale-PFIE-UE1277, Centre Val de Loire, INRA, 37380 Nouzilly, France. mickael.riou@inra.fr.
Marilyn DysartPharmajet, 400 Corporate Circle Suite N, Golden, CO 80401, USA. marilyn.dysart@pharmajet.com.
Sophie MahéUnité Virologie et Immunologie Porcines, Laboratoire de Ploufragan-Plouzané-Niort, Anses, BP 53, 22440 Ploufragan, France. sophie.mahe@anses.fr.
Elisabeth StudsrubVaccibody AS, Gaustadalleen 21, 0349 Oslo, Norway. estubsrud@vaccibody.com.
Hans NauwynckLaboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, B-9820 Merelbeke, Belgium. hans.nauwynck@ugent.be.ORCID 0000-0001-5470-0713
Nicolas BerthoVIM, INRA, Université Paris-Saclay, Domaine de Vilvert, 78350 Jouy-en-Josas, France. nicolas.bertho@inra.fr.
Olivier BourryUnité Virologie et Immunologie Porcines, Laboratoire de Ploufragan-Plouzané-Niort, Anses, BP 53, 22440 Ploufragan, France. olivier.bourry@anses.fr.ORCID 0000-0003-0220-0922
Isabelle Schwartz-CornilVIM, INRA, Université Paris-Saclay, Domaine de Vilvert, 78350 Jouy-en-Josas, France. isabelle.schwartz@inra.fr.ORCID 0000-0002-3485-1765
Université Paris-Saclay · FRCentre Val de Loire · FRAgroParisTech · FRGhent University · BEPharmaJet (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The porcine reproductive and respiratory syndrome virus (PRRSV), an RNA virus inducing abortion in sows and respiratory disease in young pigs, is a leading infectious cause of economic losses in the swine industry. Modified live vaccines (MLVs) help in controlling the disease, but their efficacy is often compromised by the high genetic diversity of circulating viruses, leading to vaccine escape variants in the field. In this study, we hypothesized that a DNA prime with naked plasmids encoding PRRSV antigens containing conserved T-cell epitopes may improve the protection of MLV against a heterologous challenge. Plasmids were delivered with surface electroporation or needle-free jet injection and European strain-derived PRRSV antigens were targeted or not to the dendritic cell receptor XCR1. Compared to MLV-alone, the DNA-MLV prime- boost regimen slightly improved the IFNγ T-cell response, and substantially increased the antibody response against envelope motives and the nucleoprotein N. The XCR1-targeting of N significantly improved the anti-N specific antibody response. Despite this immuno-potentiation, the DNA-MLV regimen did not further decrease the serum viral load or the nasal viral shedding of the challenge strain over MLV-alone. Finally, the heterologous protection, achieved in absence of detectable effective neutralizing antibodies, was not correlated to the measured antibody or to the IFNγ T-cell response. Therefore, immune correlates of protection remain to be identified and represent an important gap of knowledge in PRRSV vaccinology. This study importantly shows that a naked DNA prime immuno-potentiates an MLV, more on the B than on the IFNγ T-cell response side, and has to be further improved to reach cross-protection.

Indexed as

Immunity, HeterologousImmunization ScheduleAnimalsAntibodies, NeutralizingAntibodies, ViralImmunologic FactorsInterferon-gammaNasal MucosaPorcine Reproductive and Respiratory SyndromePorcine respiratory and reproductive syndrome virusSwineT-LymphocytesTreatment OutcomeVaccines, AttenuatedVaccines, DNAViral LoadAntibodies, NeutralizingAntibodies, ViralImmunologic FactorsInterferon-gammaVaccines, AttenuatedVaccines, DNAViral Vaccinesantigen-presenting cell targetingDNA vaccinemodified-live vaccinepigsPRRSV

Identifiers

PMID31242645
PMCPMC6631340
OpenAlexW2955833409

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.